003020.SZ · 立方制药
China A-shares · RS rating 14 · As of 2026-10-14
| Price | 16.36 CNY |
|---|---|
| 1-day change | -1.7% |
| RS rating (overall / 1M / 3M / 12M) | 14 / 40 / 43 / 11 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 20 / 16 / 2 |
| Industry group (rank) | Medical-Biomed/Biotech (68) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | -8.4% |
| Distance from 52-week high | +48.4% |
| Market cap (USD) | $590.5M |